It may sound harsh, but drug candidates that are bound to be poor performers should be identified sooner rather than later—and ruthlessly eliminated from development. Granted, early in development, ...

The desire by drug discovery researchers to conduct ADME assays earlier in the development process has led to a demand for the analysis of larger numbers of samples. Moreover, unlike the majority of ...

CN Bio, a leading provider of Organ-on-a-chip (OOC) Systems and solutions that accelerate drug discovery and development workflows, today announced the expansion of its Contract Research Services (CRS ...

The in vitro assays from CN-Bio are effective in predicting clinical outcomes. High-functioning, metabolically competent human single- and multi-organ models are used in studies on drug metabolism, ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Woburn biotech company BioTrove Inc. and New Jersey drug ...

This breakthrough has accelerated peptide drug development across multiple therapeutic areas, including cardiovascular ...

Research and Markets has announced the addition of the "ADME-Toxicology Testing - Global Strategic Business Report" report to their offering. The report provides separate comprehensive analytics for ...